Earnings ·
Reports $48.1M Q3 loss as NDA for seralutinib submitted; completes 1-for-80 reverse split
GOSSGossamer Bio, Inc.
Gossamer Bio reported a net loss of $48.1 million, or $7.36 per share, for the third quarter ended September 30, 2026, compared to a $48.2 million loss in the prior-year period. Revenue from collaborators rose to $38.4 million due to the termination of its agreement with Chiesi and reacquisition of seralutinib rights. The company submitted its first New Drug Application for seralutinib to treat pulmonary arterial hypertension in September 2026, which could unlock up to $125 million in additional committed capital upon FDA acceptance. Additionally, Gossamer completed a 1-for-80 reverse stock split in September to regain compliance with Nasdaq listing requirements. The company operates as a clinical-stage biopharmaceutical firm focused on developing seralutinib for pulmonary hypertension.